Relapse Rate Following Azathioprine Withdrawal in Maintaining Remission for Crohn's Disease: a Meta-analysis

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2011 Apr 9

PMID 21476031

Citations 17

Authors

Helen French

A Mark Dalzell

Ramesh Srinivasan

Wael El-Matary

Affiliations

Soon will be listed here.

Abstract

Background: The duration of use of azathioprine (Aza) and 6-mercaptopurine (6-MP) for maintaining remission for Crohn's disease is debatable.

Aim: To examine whether Aza/6-MP can be safely withdrawn in patients with Crohn's disease who have been in remission.

Methods: The following databases were searched: MEDLINE (1950-September 2010), EMBASE (1980-September 2010), CINHAL (1981-September 2010), PubMed (1950-September 2010), and the Cochrane Central Register of Controlled Trials (CENTRAL). Randomised controlled and cohort studies comparing azathioprine continuation versus placebo or no treatment were eligible for inclusion. Primary outcomes were relapse rate after discontinuation of Aza/6-MP at 6, 12, and 18 months, and 5 and 10 years.

Results: Five studies, with 256 patients and 168 controls, met the inclusion criteria. Stopping azathioprine/6-MP was found to significantly increase the risk of relapse at 6, 12, and 18 months with pooled odds ratios of 0.22 (95% CI 0.09-0.53), 0.25 (95% CI 0.11-0.56), and 0.35 (95% CI 0.21-0.6), respectively. Two trials examined relapse rate at 5 years with pooled OR 0.53 (95% CI 0.13-2.21). No trials looking at relapse rates beyond 5 years were identified.

Conclusions: There is a clear benefit of continuing Aza/6-MP for at least 18 months to maintain remission for Crohn's disease patients who established remission. There is not enough evidence to provide clear guidance on whether or not to continue Aza/6-MP treatment beyond 18 months. Well-designed randomised controlled trials addressing this issue are needed.

Citing Articles

Common Mistakes in Managing Patients with Inflammatory Bowel Disease.

Gisbert J, Chaparro M J Clin Med. 2024; 13(16).

PMID: 39200937 PMC: 11355176. DOI: 10.3390/jcm13164795.

Azathioprine promotes intestinal epithelial cell differentiation into Paneth cells and alleviates ileal Crohn's disease severity.

Ragab M, Schlichting H, Hicken M, Mester P, Hirose M, Almeida L Sci Rep. 2024; 14(1):12879.

PMID: 38839896 PMC: 11153537. DOI: 10.1038/s41598-024-63730-4.

Discontinuation of therapy in inflammatory bowel disease: Current views.

Mestrovic A, Kumric M, Bozic J World J Clin Cases. 2024; 12(10):1718-1727.

PMID: 38660068 PMC: 11036474. DOI: 10.12998/wjcc.v12.i10.1718.

Thiopurine Methyltransferase Activity and Thiopurine Metabolites in Inflammatory Bowel Disease.

El-Matary W Crohns Colitis 360. 2023; 2(3):otaa062.

PMID: 36798512 PMC: 9927816. DOI: 10.1093/crocol/otaa062.

Clinical Considerations Regarding the Use of Thiopurines in Older Patients with Inflammatory Bowel Disease.

Calafat M, Manosa M, Canete F, Domenech E Drugs Aging. 2021; 38(3):193-203.

PMID: 33438138 DOI: 10.1007/s40266-020-00832-4.

References

Bouhnik Y, Lemann M, Mary J, Scemama G, Tai R, Matuchansky C . Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996; 347(8996):215-9. DOI: 10.1016/s0140-6736(96)90402-x. View

Bernstein C, Fried M, Krabshuis J, Cohen H, Eliakim R, Fedail S . World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis. 2009; 16(1):112-24. DOI: 10.1002/ibd.21048. View

Holtmann M, Krummenauer F, Claas C, Kremeyer K, Lorenz D, Rainer O . Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients. Dig Dis Sci. 2006; 51(9):1516-24. DOI: 10.1007/s10620-005-9037-5. View

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

ODonoghue D, Dawson A, Powell-Tuck J, Bown R, Lennard-Jones J . Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet. 1978; 2(8097):955-7. DOI: 10.1016/s0140-6736(78)92524-2. View

Markowitz J, Rosa J, Grancher K, Aiges H, Daum F . Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology. 1990; 99(5):1347-51. DOI: 10.1016/0016-5085(90)91160-8. View

Shanahan F, Bernstein C . The evolving epidemiology of inflammatory bowel disease. Curr Opin Gastroenterol. 2009; 25(4):301-5. DOI: 10.1097/MOG.0b013e32832b12ef. View

Lemann M, Mary J, Colombel J, Duclos B, Soule J, Lerebours E . A randomized, double-blind, controlled withdrawal trial in Crohn's disease patients in long-term remission on azathioprine. Gastroenterology. 2005; 128(7):1812-8. DOI: 10.1053/j.gastro.2005.03.031. View

Sokol H, Seksik P, Nion-Larmurier I, Vienne A, Beaugerie L, Cosnes J . Current smoking, not duration of remission, delays Crohn's disease relapse following azathioprine withdrawal. Inflamm Bowel Dis. 2009; 16(3):362-3. DOI: 10.1002/ibd.20981. View

10.

Egger M, Davey Smith G, Schneider M, Minder C . Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-34. PMC: 2127453. DOI: 10.1136/bmj.315.7109.629. View

11.

Carter M, Lobo A, Travis S . Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004; 53 Suppl 5:V1-16. PMC: 1867788. DOI: 10.1136/gut.2004.043372. View

12.

Nyman M, Hansson I, Eriksson S . Long-term immunosuppressive treatment in Crohn's disease. Scand J Gastroenterol. 1985; 20(10):1197-203. DOI: 10.3109/00365528509089276. View

13.

Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R . A controlled double blind study of azathioprine in the management of Crohn's disease. Gut. 1995; 37(5):674-8. PMC: 1382873. DOI: 10.1136/gut.37.5.674. View

14.

Smith M, Irving P, Marinaki A, Sanderson J . Review article: malignancy on thiopurine treatment with special reference to inflammatory bowel disease. Aliment Pharmacol Ther. 2010; 32(2):119-30. DOI: 10.1111/j.1365-2036.2010.04330.x. View

15.

Treton X, Bouhnik Y, Mary J, Colombel J, Duclos B, Soule J . Azathioprine withdrawal in patients with Crohn's disease maintained on prolonged remission: a high risk of relapse. Clin Gastroenterol Hepatol. 2008; 7(1):80-5. DOI: 10.1016/j.cgh.2008.08.028. View

16.

Higgins J, Thompson S, Deeks J, Altman D . Measuring inconsistency in meta-analyses. BMJ. 2003; 327(7414):557-60. PMC: 192859. DOI: 10.1136/bmj.327.7414.557. View

17.

Korelitz B, Mirsky F, Fleisher M, Warman J, Wisch N, Gleim G . Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol. 1999; 94(11):3248-53. DOI: 10.1111/j.1572-0241.1999.01530.x. View

18.

Prefontaine E, Sutherland L, MacDonald J, Cepoiu M . Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev. 2009; (1):CD000067. DOI: 10.1002/14651858.CD000067.pub2. View

19.

Vilien M, Dahlerup J, Munck L, Norregaard P, Gronbaek K, Fallingborg J . Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year. Aliment Pharmacol Ther. 2004; 19(11):1147-52. DOI: 10.1111/j.1365-2036.2004.01944.x. View

20.

Kim P, Zlatanic J, Korelitz B, Gleim G . Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. Am J Gastroenterol. 1999; 94(11):3254-7. DOI: 10.1111/j.1572-0241.1999.01532.x. View